JP2011505864A5 - - Google Patents

Download PDF

Info

Publication number
JP2011505864A5
JP2011505864A5 JP2010538844A JP2010538844A JP2011505864A5 JP 2011505864 A5 JP2011505864 A5 JP 2011505864A5 JP 2010538844 A JP2010538844 A JP 2010538844A JP 2010538844 A JP2010538844 A JP 2010538844A JP 2011505864 A5 JP2011505864 A5 JP 2011505864A5
Authority
JP
Japan
Prior art keywords
peptide
nucleic acid
host cell
vector
acid sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2010538844A
Other languages
English (en)
Japanese (ja)
Other versions
JP5487117B2 (ja
JP2011505864A (ja
Filing date
Publication date
Priority claimed from EP07291602A external-priority patent/EP2077278A1/fr
Application filed filed Critical
Publication of JP2011505864A publication Critical patent/JP2011505864A/ja
Publication of JP2011505864A5 publication Critical patent/JP2011505864A5/ja
Application granted granted Critical
Publication of JP5487117B2 publication Critical patent/JP5487117B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2010538844A 2007-12-21 2008-12-18 ニューロテンシン受容体3に由来するペプチドおよび精神疾患の治療におけるその使用 Active JP5487117B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP07291602.6 2007-12-21
EP07291602A EP2077278A1 (fr) 2007-12-21 2007-12-21 Peptide dérivé du récepteur 3 de la neurotensine et utilisation dans le traitemement de maladies psychiatriques
PCT/FR2008/001784 WO2009103898A1 (fr) 2007-12-21 2008-12-18 Peptide derive du recepteur 3 de la neurotensine et utilisation dans le traitement de maladies psychiatriques

Publications (3)

Publication Number Publication Date
JP2011505864A JP2011505864A (ja) 2011-03-03
JP2011505864A5 true JP2011505864A5 (enExample) 2012-02-16
JP5487117B2 JP5487117B2 (ja) 2014-05-07

Family

ID=39304741

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2010538844A Active JP5487117B2 (ja) 2007-12-21 2008-12-18 ニューロテンシン受容体3に由来するペプチドおよび精神疾患の治療におけるその使用

Country Status (7)

Country Link
US (1) US8252748B2 (enExample)
EP (2) EP2077278A1 (enExample)
JP (1) JP5487117B2 (enExample)
AT (1) ATE535543T1 (enExample)
CA (1) CA2709907C (enExample)
ES (1) ES2377489T3 (enExample)
WO (1) WO2009103898A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2077278A1 (fr) * 2007-12-21 2009-07-08 Centre National de la Recherche Scientifique (CNRS) Peptide dérivé du récepteur 3 de la neurotensine et utilisation dans le traitemement de maladies psychiatriques
EP3099313B1 (en) 2014-01-27 2021-04-21 Centre National De La Recherche Scientifique Retro-inverso analogs of spadin display increased antidepressant effects
CA3006313C (en) * 2015-11-24 2020-02-11 Transfert Plus, S.E.C. Peptide compounds and peptide conjugates for the treatment of cancer through receptor-mediated chemotherapy
FR3057267A1 (fr) 2016-10-11 2018-04-13 Centre National De La Recherche Scientifique - Cnrs - Procede de diagnostic/determination de l'efficacite de traitement de la depression
FR3057266B1 (fr) * 2016-10-11 2021-05-21 Centre Nat Rech Scient Peptides derives du propeptide ntsr3 et leur utilisation dans le traitement de la depression

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1051485A1 (en) * 1998-01-27 2000-11-15 Smithkline Beecham Plc Trek-1 like two pore potassium channel
DK1891966T3 (da) * 2002-12-20 2012-04-02 Lundbeck & Co As H Modulation af neurotrophinaktivitet; fremgangsmåde til screening
EP2077278A1 (fr) * 2007-12-21 2009-07-08 Centre National de la Recherche Scientifique (CNRS) Peptide dérivé du récepteur 3 de la neurotensine et utilisation dans le traitemement de maladies psychiatriques

Similar Documents

Publication Publication Date Title
JP2012095652A5 (enExample)
JP2011511805A5 (enExample)
JP2009268467A5 (enExample)
NZ590466A (en) Treatment of inflammatory diseases with mammal beta defensins
JP2008508859A5 (enExample)
JP2009225798A5 (enExample)
BR112014007469A2 (pt) arcabouços de proteína com base em repetição de fibronectina tipo iii com superfícies de ligação alternativas
JP2010088434A5 (enExample)
JP2011136997A5 (enExample)
JP2011528332A5 (enExample)
JP2011505864A5 (enExample)
JP2009542812A5 (enExample)
JP2010166916A5 (enExample)
FI3581650T3 (fi) IX-tekijän polypeptidimutantti, sen käyttöjä ja menetelmä sen valmistamiseksi
JP2012500090A5 (enExample)
JP2011528896A5 (enExample)
WO2009132656A3 (en) Crystal structure of human sortilin and uses thereof for identifying ligands to sortilin
JP2012503478A5 (enExample)
NO20084488L (no) Methods for the production of functional protein from DNA having a nonsense mutation and the treatment of disorders associated therewith
WO2013056049A3 (en) Tubular prostheses
NZ597601A (en) Treatment and prevention of influenza
JP2014520527A5 (enExample)
JP2013531491A5 (enExample)
WO2013093029A3 (en) Variants of yeast ndi1 gene, and uses thereof in the treatment of disease associated with mitochondrial dysfunction
JP2010183921A5 (enExample)